Details of the Active Pharmaceutical Ingredient (API)

General Information of API (ID: D00209)
Name
Dolasetron
Synonyms    Click to Show/Hide the Synonyms of This API
dolasetron; 115956-12-2; LSM-5418; Anzemet Cinv; 1H-Indole-3-carboxylic acid, octahydro-3-oxo-2,6-methano-2H-quinolizin-8-yl ester, stereoisomer; SCHEMBL42063; SCHEMBL42064; BIDD:GT0287; ZINC2688; CHEMBL2368925; DTXSID4048276; CHEBI:94561; HMS3886C21; HY-B0750; 3594AH; BDBM50451546; AKOS022184758; AKOS025404537; ZINC100019093; ZINC100038399; ZINC103105084; CCG-267749; CS-3747; DB00757; NCGC00181048-08; (2alpha,6alpha,8alpha,9abeta)-octahydro-3-oxo-2,6-methano-2h-quinolizin-8-yl-1h-indole-3-carboxylate; AS-74586; 115956-13-3; AB00698337-03; SR-05000001488; Q-101000; Q1829318; SR-05000001488-1; BRD-K28029915-001-02-2; Q27166396; (1s,3R,5s,7S)-10-oxo-8-azatricyclo[5.3.1.0(3),?]undecan-5-yl 1H-indole-3-carboxylate; (2R,6R,8R,9aS)-3-oxooctahydro-2H-2,6-methanoquinolizin-8-yl 1H-indole-3-carboxylate
Clinical Status
Approved
Disease Indication Functional nausea/vomiting ICD-11: DD90 [1]
PubChem CID
3033818
Formula
C19H20N2O3
Canonical SMILES
C1[C@@H]2CC(C[C@H]3N2CC(=O)C1C3)OC(=O)C4=CNC5=CC=CC=C54
InChI
1S/C19H20N2O3/c22-18-10-21-12-5-11(18)6-13(21)8-14(7-12)24-19(23)16-9-20-17-4-2-1-3-15(16)17/h1-4,9,11-14,20H,5-8,10H2/t11?,12-,13+,14?
InChIKey
UKTAZPQNNNJVKR-AKJUYKBHSA-N
   Click to Show/Hide the Molecular Data (Structure/Property) of This API
Structure
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=3033818"></iframe>
3D MOL 2D MOL
Physicochemical Properties Molecular Weight 324.4 Topological Polar Surface Area 62.4
XlogP 3.4 Complexity 535
Heavy Atom Count 24 Rotatable Bond Count 3
Hydrogen Bond Donor Count 1 Hydrogen Bond Acceptor Count 4
Full List of Drug Formulations (DFMs) Containing This API
          Dolasetron 100 mg tablet Click to Show/Hide the Full List of Formulation(s):          2 Formulation(s)
             Drug Formulation 1 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Lactose; Magnesium stearate; Ferric oxide red; Ferrosoferric oxide; Propylene glycol; Titanium dioxide; Croscarmellose sodium; Polysorbate 80; Carnauba wax; Hypromelloses; Polyethylene glycols; White wax
                   Dosage Form Oral Tablet
                   Company Sanofi-Aventis
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
Propylene glycol DIG Info Albendazole monooxygenase (Inhibition ratio < 20 %) [2]
Polysorbate 80 DIG Info Prostaglandin G/H synthase 1 (IC50 = 1 uM) [3]
Magnesium stearate DIG Info Albendazole monooxygenase (Protein expression downregulation) [4]
Carmellose sodium DIG Info Albendazole monooxygenase (Protein expression upregulation) [4]
             Drug Formulation 2 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Lactose; Magnesium stearate; Ferric oxide red; Ferrosoferric oxide; Propylene glycol; Titanium dioxide; Croscarmellose sodium; Polysorbate 80; Carnauba wax; Hypromelloses; Polyethylene glycols; Shellac; Starch, pregelatinized corn; White wax
                   Dosage Form Oral Tablet
                   Company Avera McKennan Hospital; Validus Pharmaceuticals
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
Propylene glycol DIG Info Albendazole monooxygenase (Inhibition ratio < 20 %) [2]
Polysorbate 80 DIG Info Prostaglandin G/H synthase 1 (IC50 = 1 uM) [3]
Magnesium stearate DIG Info Albendazole monooxygenase (Protein expression downregulation) [4]
Carmellose sodium DIG Info Albendazole monooxygenase (Protein expression upregulation) [4]
          Dolasetron 50 mg tablet Click to Show/Hide the Full List of Formulation(s):          2 Formulation(s)
             Drug Formulation 1 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Lactose; Magnesium stearate; Ferric oxide red; Ferrosoferric oxide; Propylene glycol; Titanium dioxide; Croscarmellose sodium; Polysorbate 80; Carnauba wax; Hypromelloses; Polyethylene glycols; White wax
                   Dosage Form Oral Tablet
                   Company Sanofi-Aventis
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
Propylene glycol DIG Info Albendazole monooxygenase (Inhibition ratio < 20 %) [2]
Polysorbate 80 DIG Info Prostaglandin G/H synthase 1 (IC50 = 1 uM) [3]
Magnesium stearate DIG Info Albendazole monooxygenase (Protein expression downregulation) [4]
Carmellose sodium DIG Info Albendazole monooxygenase (Protein expression upregulation) [4]
             Drug Formulation 2 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Lactose; Magnesium stearate; Ferric oxide red; Ferrosoferric oxide; Propylene glycol; Titanium dioxide; Croscarmellose sodium; Polysorbate 80; Carnauba wax; Hypromelloses; Polyethylene glycols; Shellac; Starch, pregelatinized corn; White wax
                   Dosage Form Oral Tablet
                   Company Validus Pharmaceuticals
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
Propylene glycol DIG Info Albendazole monooxygenase (Inhibition ratio < 20 %) [2]
Polysorbate 80 DIG Info Prostaglandin G/H synthase 1 (IC50 = 1 uM) [3]
Magnesium stearate DIG Info Albendazole monooxygenase (Protein expression downregulation) [4]
Carmellose sodium DIG Info Albendazole monooxygenase (Protein expression upregulation) [4]
References
1 FDA label for approved dolasetron from the official website of the U.S. Food and Drug Administration.
2 Pharmaceutical excipients inhibit cytochrome P450 activity in cell free systems and after systemic administration. Eur J Pharm Biopharm. 2008 Sep;70(1):279-88.
3 The activities of drug inactive ingredients on biological targets. Science. 2020 Jul 24;369(6502):403-413.
4 Effects of commonly used excipients on the expression of CYP3A4 in colon and liver cells. Pharm Res. 2010 Aug;27(8):1703-12.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.